Compare American Superconductor Corporation (AMSC) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs Cigna Corp — how do they compare? American Superconductor Corporation trades at $32.3 (market cap $1.56B), while Cigna Corp trades at $277.8 (market cap $73.30B). The key difference: Cigna Corp is far larger — about 47× American Superconductor Corporation's market cap, and Cigna Corp pays a 2.25% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| AMSC | CI | |
|---|---|---|
Market Cap | $1.56B | $73.30B |
Sector | Technology | Health |
52-Week High | $66.68 | $311.00 |
52-Week Low | $25.95 | $244.41 |
Enterprise Value | $1.42B | $98.01B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $32.28, up 4.16% today, but faces a bearish technical outlook with 14 sell signals versus 3 buys. The company reported strong revenue growth with Q1 2026 sales up 30% to $94.1M (Zacks, Aug 7, 2026) and a record backlog over $400M, though Q2 earnings missed estimates amid margin pressure. Net income margin improved dramatically to 42.56% in 2026 from 2.7% in 2025, but cash flow turned negative with a $60M net outflow in 2026.
The stock presents a mixed opportunity: robust order growth and expanding margins support upside, but high EV/EBITDA (65.73) and technical weakness pose risks. Analyst consensus is bullish (53% Buy), yet investors should watch execution on backlog conversion and margin sustainability amid competitive and cost pressures.
Cigna (CI) trades at $278.15, showing slight daily weakness but maintaining a strong fundamental profile with consistent earnings beats. The stock appears undervalued with a P/E of 11.51 and P/S of 0.26, while technical indicators show bearish momentum near key support at $271. Recent Q2 2026 results exceeded expectations with EPS of $7.78 versus $7.60 estimates, driving management's raised full-year guidance.
Cigna presents a compelling value opportunity with analyst consensus pointing to 22% upside to the $338.90 price target. However, near-term technical pressure and competitive healthcare margins require monitoring. The company's stable dividend payments and institutional accumulation support long-term confidence despite current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
